These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11824001)

  • 41. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
    GUSTO investigators
    N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Efficacy of thrombolytic therapy using reteplase in cases with acute ST-segment elevation myocardial infarction: results from a multicenter clinical trial].
    Liu XY; Zhang Y; Li MW; Wang XP; Qi DD; Hao PY; Zhang H; Cheng QQ; Zhao LS; Gao CY; Hu DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Sep; 44(9):766-770. PubMed ID: 27667274
    [No Abstract]   [Full Text] [Related]  

  • 43. Post-Reteplase Evaluation of Clinical Safety & Efficacy in Indian Patients (Precise-In Study).
    Singh RK; Trailokya A; Naik MM
    J Assoc Physicians India; 2015 Apr; 63(4):30, 32-5. PubMed ID: 26591167
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reteplase in acute myocardial infarction.
    Busti AJ; Marshall KS; Hooper JS
    JAMA; 2004 May; 291(20):2429-30; author reply 2430. PubMed ID: 15161887
    [No Abstract]   [Full Text] [Related]  

  • 45. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
    Massel D
    Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimal thrombolytic strategies for acute myocardial infarction--bolus administration.
    McMechan SR; Adgey AA
    QJM; 1998 Nov; 91(11):719-25. PubMed ID: 10024933
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective.
    Martin U; Kaufmann B; Neugebauer G
    Clin Pharmacokinet; 1999 Apr; 36(4):265-76. PubMed ID: 10320949
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Facilitated percutaneous coronary intervention (PCI) in patients with acute ST-elevation myocardial infarction: comparison of prehospital tirofiban versus fibrinolysis before direct PCI.
    Möckel M; Bocksch W; Strohm S; Kühnle Y; Vollert J; Nibbe L; Dietz R
    Int J Cardiol; 2005 Aug; 103(2):193-200. PubMed ID: 16080980
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical trial results with a new plasminogen activator.
    Bode C; Peter K; Moser M; Smalling RW; Weaver WD
    Eur Heart J; 1997 Dec; 18 Suppl F():F17-21. PubMed ID: 9447336
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The prevention of reocclusion after thrombolysis in acute myocardial infarct: is tissue-type plasminogen activator really superior to streptokinase?].
    Negrini M
    G Ital Cardiol; 1995 Apr; 25(4):511-5. PubMed ID: 7677921
    [No Abstract]   [Full Text] [Related]  

  • 52. Comparative case fatality analysis of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial: variation by country beyond predictive profile. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
    Barbash GI; Modan M; Goldbourt U; White HD; Van de Werf F
    J Am Coll Cardiol; 1993 Feb; 21(2):281-6. PubMed ID: 8425987
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reteplase (r-PA): a new plasminogen activator.
    Bode C; Kohler B; Moser M; Schmittner M; Smalling RW; Strasser RH
    Expert Opin Investig Drugs; 1997 Aug; 6(8):1099-104. PubMed ID: 15989667
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ISIS and the emergence of large, simple trials.
    Altman DG
    Lancet; 2015 Aug; 386(9994):636-7. PubMed ID: 26334142
    [No Abstract]   [Full Text] [Related]  

  • 55. Three-pronged innovation to improve care for acute myocardial infarction patients in Cuba.
    Giraldo G
    MEDICC Rev; 2010 Jul; 12(3):11-6. PubMed ID: 20697332
    [No Abstract]   [Full Text] [Related]  

  • 56. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis.
    Pogue JM; Yusuf S
    Control Clin Trials; 1997 Dec; 18(6):580-93; discussion 661-6. PubMed ID: 9408720
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A perspective on the regulation of the evaluation of new antithrombotic drugs.
    Califf RM
    Am J Cardiol; 1998 Oct; 82(8B):25P-35P. PubMed ID: 9809889
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multiple testing to establish superiority/equivalence of a new treatment compared with kappa standard treatments.
    Dunnett CW; Tamhane AC
    Stat Med; 1997 Nov; 16(21):2489-506. PubMed ID: 9364656
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Establishing equivalence by showing that a specified percentage of the effect of the active control over placebo is maintained.
    Holmgren EB
    J Biopharm Stat; 1999 Nov; 9(4):651-9. PubMed ID: 10576409
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reteplase versus Streptokinase in Management of ST-segment Elevation Myocardial Infarction; a Letter to the Editor.
    Giahchi F; Mohammadi M
    Adv J Emerg Med; 2019; 3(4):e34. PubMed ID: 31633089
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.